Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN6051 plus anlotinib in advanced or refractory soft tissue sarcoma
CTR20220006Phase 2Active
- Sponsor
- Lijin Biotech
- Start
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of exlinkibart, anlotinib in soft tissue sarcoma (STS), sponsored by Lijin Biotech. Started Jul 2022; status: active.
02
Drugs
exlinkibartanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20220006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220006.